Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma

Learn more about:
Related Clinical Trial
A Phase 1, Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas AMG 319 Lymphoid Malignancy FIH Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Tandem Auto-Allo Transplant for Lymphoma Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas CD4CAR for CD4+ Leukemia and Lymphoma Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma A Study for Patients With Non-Hodgkin’s Lymphomas High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Allo-HSCT as First-line Consolidation in High-risk PTCL A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low ( T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Gemcitabine in NK/T Cell Lymphoma A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma Trial of Endostar Combined With CHOPT for T Cell Lymphoma Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Brief Title

Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma

Official Title

BrUOG 273:Cellular Immunotherapy For Refractory Hematological Malignancies:A Brown University Oncology Research Group Study

Brief Summary

      The study of whether an infusion of blood cells called lymphocytes from a donor can stimulate
      the immune system to fight your leukemia/lymphoma.

Detailed Description

      There have been important advances in the modulation of the immune system for the treatment
      of hematologic malignancies and solid tumors.

      This protocol will build upon these previous observations as follows:

        -  Haploidentical peripheral blood pheresed cells will be used at 1-2x108 CD3 cells/kg.

        -  Total body radiation will not be utilized.

             -  This modification may more effectively activate the recipient's immune system to
                attack their hematological malignancy by not damaging the recipient's immune cells
                prior to cellular infusion. Safety should be improved since the risk of graft
                versus host disease should be greatly reduced as the host's immune system will not
                be conditioned.

        -  Granulocyte-colony stimulating factor (G-CSF) priming will not be used.

             -  In our first clinical trial, G-CSF priming was not used for matched transplants.
                Our second trial did employ G-CSF priming in the haplo-identical setting. Previous
                data has cited a role for G-CSF in stimulation of invariant Natural Killer(NK)
                cells with enhanced GVL effects11. However, our most recent laboratory data with
                unprimed PBMC has shown effective cell kill activity without the addition of G-CSF.
                As G-CSF would be administered to healthy volunteers, the unclear benefit of the
                addition of this cytokine is offset by the potential side effects such as headache,
                fever, and bone pain. G-CSF mobilization serves to shift the response from a TH1 to
                TH2 through the increased production of T regulatory cells. The end result would be
                a decrease in immune stimulation. Since the goal of this study is to NOT have
                engraftment, the manipulation of the donor cells to dampen the host versus tumor
                stimulation is not needed nor desired. Furthermore, since this protocol is not a
                stem cell transplant, stem cells do not need to be mobilized with G-CSF.

      It is important to note that the proposed study is not a stem cell transplant study. In the
      situation of stem cell transplants, the goal of the procedure is to have engraftment, or
      sustainable donor chimerism in the marrow to provide hematopoietic reconstitution as well as
      immunologic reconstitution. In this study, we are evaluating the use of donor lymphocytes
      (not stem cells) to stimulate an immune response of the recipients' immune system.

Study Phase

Phase 2

Study Type


Primary Outcome

Overall Response Rate of Cellular Immune Therapy With HLA Haploidentical Peripheral Blood Pheresed Cells in Patients With Relapsed/Refractory Hematological Malignancies.

Secondary Outcome

 To Evaluate the Rate of Dose Limiting Toxicities of HLA Haploidentical Peripheral Blood Pheresed Cellular Infusions.


Mantle Cell Lymphoma


cellular immunotherapy

Study Arms / Comparison Groups

 cellular immunotherapy
Description:  A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor will be infused, irrespective of the number of CD34+ cells.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 2013

Completion Date

June 2015

Primary Completion Date

June 2015

Eligibility Criteria

        Inclusion Criteria:

          -  Histologic confirmation of hematological malignancy consisting of the following

          -  Mantle cell lymphoma with Ki-67>30%

          -  Diffuse Large Cell Lymphoma

          -  Burkitts Lymphoma

          -  Systemic T Cell Lymphomas

          -  Acute Myeloid Leukemia

          -  Acute Lymphoblastic Leukemia

          -  Recurrence or progression of hematological malignancy after at least 1 prior standard
             treatment with progression within 6 months from last treatment.

          -  No curative treatment option is available.

             -> 4-weeks since prior chemotherapy or radiation to cellular therapy infusion.
             (Hydroxyurea may be utilized up to 48 hours prior to initiation of treatment on this

          -  Age equal to or greater than 18 years.

          -  Patients with a history of invasive second malignancy unless disease free for > 5

          -  Patients must have an expected life expectancy of at least 2 months at the time of
             initiation of treatment.

          -  No active systemic infection.

          -  Patients who have relapsed after standard autologous stem cell infusion are eligible
             as long as they meet all inclusion criteria and no exclusion criteria. These patients
             must be out more than 6 months from cell infusion to be eligible for enrollment.

          -  DLCO > 40% with no symptomatic pulmonary disease.

          -  LVEF > 40% by MUGA or echocardiogram.

          -  Creatinine < 2.0 mg/dl. Total bilirubin less than 1.5x the upper limit of normal
             (ULN), AST < 3x ULN.

          -  Non-pregnant and willing to use appropriate birth control during the duration of the
             study period.

        Exclusion Criteria:

          -  Evidence of HIV infection.

          -  Any uncontrolled severe, concurrent illness which in the opinion of the treating
             physician would make this protocol treatment unreasonably hazardous for the patient.

          -  Oxygen dependent obstructive pulmonary disease.

          -  Failure to demonstrate adequate compliance with medical therapy and follow-up.

          -  Significant medical or psychiatric illness that would impair the ability to
             participate in protocol therapy.

          -  For women of reproductive potential, refusal to use effective form of contraception.

          -  Previous allogeneic stem cell transplant

          -  Patients who have had previous purine analog (fludarabine, pentostatin, 2-CDA)
             -Patients with chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL),
             multiple myeloma, and indolent lymphoma (follicular lymphoma, marginal zone lymphoma)

          -  Patients with HLA antibodies to donor HLA type.




18 Years - N/A

Accepts Healthy Volunteers



Peter Quesenberry, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID

BrUOG 273

Responsible Party


Study Sponsor

Brown University

Study Sponsor

Peter Quesenberry, MD, Principal Investigator, Brown University

Verification Date

February 2022